The other estimated subtypes had a significantly worse DRFS compared to HR+/HER2+ breast cancer in stage B (HR−/HER2+ p < 0.01; HR−/HER2− p < 0.001, Supplementary Table S6). This evidence concerns the gene ERBB2 and breast cancer.